Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
94.31
(
-0.74%
)
Bitcoin
76,282.22
(
-0.06%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: GrthzGd post# 186390

Wednesday, 01/21/2015 1:11:26 PM

Wednesday, January 21, 2015 1:11:26 PM

Post# of 257432

ENTA—what about HBV, which...is quite a problem in Europe, and for which there is still no cure. Could their drugs reach that?

DAAs for HCV don’t work against HBV (and vice-versa); ENTA has never revealed any interest in HBV, so I presume they’re not pursing it.

The premiere developer of new drugs for HBV is probably the recently announced OnCore-TKMR combination (#msg-109820030, #msg-109841768).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today